BiTE Immunotherapy Trial Aims to Improve Survival in High-Risk Kinase-Driven B-ALL

Overview

A phase 3 clinical trial is investigating whether adding blinatumomab, a bispecific T-cell engager (BiTE) immunotherapy, to chemotherapy plus tyrosine kinase inhibitors (TKIs) can improve survival in pediatric, adolescent, and young adult patients with Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL). The study also aims to reduce long-term toxicities by replacing traditional consolidation chemotherapy with this targeted approach.

Background

Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL are genetic subtypes of childhood B-ALL associated with poorer outcomes compared to other subtypes. Although the addition of TKIs such as imatinib and dasatinib to chemotherapy has improved survival, the five-year overall survival remains around 80%. Blinatumomab (Blincyto), a BiTE antibody, directs T cells to target CD19 on B-ALL cells, enhancing immune-mediated leukemia cell killing. The current trial (NCT06124157) led by the Children’s Oncology Group and Roswell Park Comprehensive Cancer Center evaluates whether combining blinatumomab with TKIs and chemotherapy can further improve outcomes in patients under 25 years old with newly diagnosed Ph+ or Ph-like B-ALL.

Data Highlights

The trial assigns patients based on molecular subtype: Ph+ B-ALL patients receive a modified Berlin-Frankfurt-Münster (BFM) chemotherapy regimen with three cycles of blinatumomab and continuous dasatinib, omitting traditional consolidation chemotherapy. Ph-like B-ALL patients receive the modified BFM chemotherapy plus continuous imatinib (for PDGFRB gene fusions) or dasatinib (for other cases), also without traditional consolidation chemotherapy. Primary endpoints include safety, toxicity, and three-year overall, event-free, and disease-free survival.

Key Findings

• Ph+ and Ph-like B-ALL subtypes have historically inferior treatment outcomes with approximately 80% five-year overall survival despite TKI addition.
• Blinatumomab is a bispecific T-cell engager that targets CD19 on B-ALL cells, harnessing the immune system for targeted leukemia cell killing.
• The trial replaces traditional consolidation chemotherapy with blinatumomab-containing chemo-immunotherapy to potentially reduce long-term toxicities.
• Patients under 25 years with newly diagnosed Ph+ or Ph-like B-ALL are enrolled and assigned treatment based on molecular subtype and gene fusion status.
• The study evaluates safety, toxicity, and three-year survival outcomes to determine if this targeted approach improves prognosis.

Clinical Implications

This trial represents a novel strategy combining immunotherapy with targeted kinase inhibition and chemotherapy to improve survival in high-risk pediatric B-ALL subtypes. If successful, it may establish a new standard of care that reduces reliance on traditional cytotoxic consolidation chemotherapy, potentially lowering long-term treatment-related toxicities. Clinicians should consider molecular subtype and gene fusion status when selecting targeted therapies for these patients.

Conclusion

The ongoing phase 3 trial integrating blinatumomab with TKIs and chemotherapy aims to improve survival and reduce toxicity in young patients with Ph+ and Ph-like B-ALL. Its results could significantly impact treatment paradigms for these high-risk leukemia subtypes.

References

1. Niswander et al. 2024 -- Phase 3 Trial of Blinatumomab with TKIs in Pediatric Ph+ and Ph-like B-ALL